On Monday, Enzolytics’s stock was at $0.216. However, today’s pre-market stock is currently at $0.189, resulting in a 12% loss. But that can change very soon amid recent developments. Enzolytics and Lonza Bioscience agreed to combine their technologies to fastly track the development and production of anti-HIV and anti-SARS-CoV-2 Monoclonal Antibodies produced by Enzolytics.
Lonza is an international chemicals and biotechnology company with facilities in Europe, North America, and South Asia. It has a deep development and manufacturing capability using advanced technologies to fastly and productively accelerate the final production of monoclonal antibodies, complex proteins, and recombinant proteins.
Working from sequences of the antibodies produced by Enzolytics, Lonza will provide manufacturing, developability, stability assessment, process development, and production of a stable cell line. Moreover, the application of Lonza’s technology will drastically decrease the development time and fast-tracks the IND application for both anti-HIV and anti-SARS-CoV-2 Monoclonal Antibodies.
Writing for business and finance publishers has become his passion over the last decades after he completed a master’s degree in Financial Management. Sharing some opinions and forecasts to thousands of readers is a routine job for him but he never promises to invest in one stock.